Treatment with riboflavin and ultraviolet light prevents alloimmunization to platelet transfusions and cardiac transplants

Transplantation

Volumn 84, Issue 9, 2007, Pages 1174-1182

  Asano, Hiroshi ^a   Lee, Chih Yuan ^a   Fox Talbot, Karen ^a   Koh, Cheryl M ^a   Erdinc, Melek M ^a   Marschner, Susanne ^b   Keil, Shawn ^b   Goodrich, Raymond P ^b   Baldwin, William M ^a,c  

^a DEPARTMENT OF PATHOLOGY   (United States)

^b Navigant Biotechnologies Inc   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antibodies; Complement; Sensitization; Transfusions

Indexed keywords

CD45 ANTIGEN; COMPLEMENT COMPONENT C4D; CYCLOSPORIN; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; LIPOCORTIN 5; RIBOFLAVIN;

ALLOIMMUNIZATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CARDIAC GRAFT REJECTION; CELL INFILTRATION; COMPARATIVE STUDY; CONTROLLED STUDY; HEART TRANSPLANTATION; LEUKOCYTE; MACROPHAGE; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; THROMBOCYTE TRANSFUSION; ULTRAVIOLET RADIATION;

ANIMALS; HEART TRANSPLANTATION; ISOANTIBODIES; MACROPHAGES; MALE; MODELS, ANIMAL; PLATELET TRANSFUSION; RATS; RATS, INBRED LEW; RATS, INBRED STRAINS; RIBOFLAVIN; TRANSPLANTATION, HOMOLOGOUS; ULTRAVIOLET RAYS;

EID: 36248973218     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.tp.0000287318.94088.d7     Document Type: Article

References (36)

1. Massad MG, Cook DJ, Schmitt SK, et al. Factors influencing HLA sensitization in implantable LVAD recipients. Ann Thorac Surg 1997; 64: 1120.
2. Moazami N, Itescu S, Williams MR, et al. Platelet transfusions are associated with the development of anti-major histocompatibility complex class I antibodies in patients with left ventricular assist support. J Heart Lung Transplant 1998; 17: 876.
3. Tsau PH, Arabia FA, Toporoff B, et al. Positive panel reactive antibody titers in patients bridged to transplantation with a mechanical assist device: Risk factors and treatment. Asaio J 1998; 44: M634.
4. Fishbein MC, Kobashigawa J. Biopsy-negative cardiac transplant rejection: Etiology, diagnosis, and therapy. Curr Opin Cardiol 2004; 19: 166.
5. Rodriguez ER, Skojec DV, Tan CD, et al. Antibody-mediated rejection in human cardiac allografts: Evaluation of immunoglobulins and complement activation products C4d and C3d as markers. Am J Transplant 2005; 5: 2778.
6. Smith RN, Brousaides N, Grazette L, et al. C4d deposition in cardiac allografts correlates with alloantibody. J Heart Lung Transplant 2005; 24: 1202.
7. Casarez TW, Perens G, Williams RJ, et al. Humoral rejection in pediatric orthotopic heart transplantation. J Heart Lung Transplant 2007; 26: 114.
8. Grijzenhout MA, Aarts-Riemens MI, de Gruijl FR, et al. UVB irradiation of human platelet concentrates does not prevent HLA alloimmunization in recipients. Blood 1994; 84: 3524.
9. Kao KJ. Induction of humoral immune tolerance to major histocompatibility complex antigens by transfusions of UVB-irradiated leukocytes. Blood 1996; 88: 4375.
10. Leukocyte reduction and ultraviolet B irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusions. The Trial to Reduce Alloimmunization to Platelets Study Group. N Engl J Med 1997; 337: 1861.
11. Karpinski M, Pochinco D, Dembinski I, et al. Leukocyte reduction of red blood cell transfusions does not decrease allosensitization rates in potential kidney transplant candidates. J Am Soc Nephrol 2004; 15: 818.
12. Grijzenhout MA, Aarts-Riemens MI, Claas FH, van Prooijen HC. Prevention of MHC-alloimmunization by UV-B irradiation in a murine model: Effects of UV dose and number of transfused cells. Br J Haematol 1994; 87: 598.
13. Goodrich RP, Edrich RA, Li J, Seghatchian J. The Mirasoltrade mark PRT system for pathogen reduction of platelets and plasma: An overview of current status and future trends. Transfus Apher Sci 2006; 35: 5.
14. AuBuchon JP, Herschel L, Roger J, et al. Efficacy of apheresis platelets treated with riboflavin and ultraviolet light for pathogen reduction. Transfusion 2005; 45: 1335.
15. Perez-Pujol S, Tonda R, Lozano M, et al. Effects of a new pathogen-reduction technology (Mirasol PRT) on functional aspects of platelet concentrates. Transfusion 2005; 45: 911.
16. Kumar V, Lockerbie O, Keil SD, et al. Riboflavin and UV-light based pathogen reduction: Extent and consequence of DNA damage at the molecular level. Photochem Photobiol 2004; 80: 15.
17. Fast LD, Dileone G, Li J, Goodrich R. Functional inactivation of white blood cells by Mirasol treatment. Transfusion 2006; 46: 642.
18. Fast LD, DiLeone G, Cardarelli G, et al. Mirasol PRT treatment of donor white blood cells prevents the development of xenogeneic graftversus-host disease in Rag2-/-gamma c-/- double knockout mice. Transfusion 2006; 46: 1553.
19. Wasowska B, Baldwin WM III, Sanfilippo F. IgG alloantibody responses to donor specific blood transfusion in different rat strain combinations are predictive of renal allograft survival. Transplantation 1992; 53: 175.
20. Minami K, Murata K, Lee C-Y, et al. C4d deposition and clearance in cardiac transplants correlates with alloantibody levels and rejection in rats. Am J Transplant 2006; 6: 923.
21. Qian Z, Lee CY, Murata K, et al. Antibody and complement mediated injury in transplants following sensitization by allogeneic blood transfusion. Transplantation 2006; 82: 857.
22. Korb LC, Ahearn JM. C1q binds directly and specifically to surface blebs of apoptotic human keratinocytes: complement deficiency and systemic lupus erythematosus revisited. J Immunol 1997; 158: 4525.
23. Navratil JS, Watkins SC, Wisnieski JJ, Ahearn JM. The globular heads of C1q specifically recognize surface blebs of apoptotic vascular endothelial cells. J Immunol 2001; 166: 3231.
24. Nauta AJ, Trouw LA, Daha MR, et al. Direct binding of C1q to apoptotic cells and cell blebs induces complement activation. Eur J Immunol 2002; 32: 1726.
25. Nauta AJ, Castellano G, Xu W, et al. Opsonization with C1q and mannose-binding lectin targets apoptotic cells to dendritic cells. J Immunol 2004; 173: 3044.
26. Opelz G, Terasaki PI. Improvement of kidney-graft survival with increased numbers of blood transfusions. N Engl J Med 1978; 299: 799.
27. Stewart S, Winters GL, Fishbein MC, et al. Revision of the 1990 working formulation for the standardization of nomenclature in the diagnosis of heart rejection. J Heart Lung Transplant 2005; 24: 1710.
28. Baldwin WM III, Kasper EK, Zachary AA, et al. Beyond C4d: other complement related diagnostic approaches to antibody-mediated rejection. Am J Transplant 2004; 4: 311.
29. Haas M, Rahman MH, Racusen LC, et al. C4d and C3d staining in biopsies of ABO- and HLA-incompatible renal allografts: Correlation with histologic findings. Am J Transplant 2006; 6: 1829.
30. Haas M, Montgomery RA, Segev DL, et al. Subclinical acute antibody-mediated rejection in positive crossmatch renal allografts. Am J Transplant 2007; 7: 576.
31. Mengel M, Bogers J, Bosmans JL, et al. Incidence of C4d stain in protocol biopsies from renal allografts: Results from a multicenter trial. Am J Transplant 2005; 5: 1050.
32. Park WD, Grande JP, Ninova D, et al. Accommodation in ABO-incompatible kidney allografts, a novel mechanism of self-protection against antibody-mediated injury. Am J Transplant 2003; 3: 952.
33. Colvin RB, Smith RN. Antibody-mediated organ-allograft rejection. Nat Rev Immunol 2005; 5: 807.
34. Dempsey PW, Allison MED, Akkaraju S, et al. C3d of complement as a molecular adjuvant: Bridging innate and acquired immunity. Science 1996; 271: 348.
35. Gundlach M, Oluwole SF, D'Agati V, et al. Differential effects of pretreatment with ultraviolet-B modified or unmodified donor-specific leukocyte transfusions on intestinal and cardiac allograft survival in the rat. Transplantation 1992; 53: 613.
36. Wang Z, Larregina AT, Shufesky WJ, et al. Use of the inhibitory effect of apoptotic cells on dendritic cells for graft survival via T-cell deletion and regulatory T cells. Am J Transplant 2006; 6: 1297.